Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8N594

UPID:
MPND_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8N594; Q96SJ0; Q9Y2P1; Q9Y2P2

BACKGROUND:
MPN domain-containing protein, with accession number Q8N594, is implicated in crucial biological functions. Acting as a probable protease, it uniquely identifies and binds to N(6)-methyladenosine (m6A) marked DNA, leading to its targeted degradation. This activity is essential for maintaining proper gene expression levels and cellular homeostasis, as evidenced by scientific studies (PubMed:30982744).

THERAPEUTIC SIGNIFICANCE:
The exploration of MPN domain-containing protein's function offers promising avenues for drug discovery. Its critical role in recognizing and processing m6A DNA highlights its potential as a target for therapeutic intervention in conditions where gene expression is aberrant.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.